Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4
- 1 January 2000
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 17 (4) , 419-426
- https://doi.org/10.1023/a:1007572803027
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the LiverPharmacological Reviews, 1998
- Prediction of in vivo drug metabolism in the human liver from in vitro metabolism dataPharmacology & Therapeutics, 1997
- Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and NizatidinePharmaceutical Research, 1994
- A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.1993
- Pharmacokinetic Drug Interactions of MacrolidesClinical Pharmacokinetics, 1992
- Single Oral Dose Pharmacokinetics of Erythromycin and Roxithromycin and the Effects of Chronic DosingTherapeutic Drug Monitoring, 1990
- OXIDATION OF MIDAZOLAM AND TRIAZOLAM BY HUMAN-LIVER CYTOCHROME P450IIIA41989
- Kinetics of suicide substrates. Practical procedures for determining parametersBiochemical Journal, 1985
- Triazolam dispositionClinical Pharmacology & Therapeutics, 1981
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981